IVI seeks comment on its new NSCLC model through April 1, 2019.
This article was authored by Mark Linthicum, MPP, director of scientific communications at Innovation and Value Initiative
The adoption of value-based payments continues to grow, albeit slowly. About half of 150 healthcare executives who responded to a recent survey said that between half and three-quarters of their current contracts are in value-based models. This confirms other data that show US healthcare payments tied to value-based care increased in 2017 to 34%, an increase from 23% over 2 years.
Value-based healthcare is predicated on collaboration. Sharing of data, methods, pathways and perspectives among different stakeholders is paramount if the transition to value-based care is to be fully realized.
But does value mean the same thing to a patient and an insurer? A physician? An employer? Each of the stakeholders affected by value-based care has a unique perspective on what actually constitutes value. For value-based healthcare to succeed, all these perspectives must be honored and included.
Instead of relying solely on legacy methods to measure value, a process for all stakeholder perspectives to be heard and addressed is needed. But until now, there hasn’t been a transparent process for doing so, leaving decision makers who measure value from payer, employer, patient and manufacturer perspectives relegated to their separate camps.
That’s why the Innovation and Value Initiative launched the Open-Source Value Platform (OSVP). The OSVP uses a transparent and open-source process to develop methods and tools to estimate the value of medical technologies in a way that is patient-centric, allows for a broad range of perspectives, incorporates the latest available evidence and considers the full range of scientifically defensible approaches.
The OSVP isn’t intended to be single framework for measuring value. Rather, it’s a platform and process to build trust and collaboration with the goal of finding common ground and improved approaches that unlock value for the ultimate consumer in healthcare: patients. We invite your participation.
Last month IVI launched its second disease-specific value assessment platform for measuring the relative value of sequential treatments for epidermal growth factor receptor positive non-squamous non-small cell lung cancer (NSCLC), which can be found on our website. IVI’s disease-specific models serve as a laboratory to test and improve approaches to value assessment, and as a forum for collaboration across all stakeholders. Models evolve over time, driven by the feedback we receive during open public comment periods from stakeholders like you.
The public comment period for our new NSCLC model will remain open until April 1, 2019, and IVI highly encourages and welcomes comments, suggestions and critiques. Please take the time to take a tour and examine the model and consider providing your comments.
We think the only avenue to realize value--in outcomes, costs, quality and patient experience--is through transparency, collaboration and iteration. We hope by commenting on the NSCLC model, you’ll join us taking an important step on the value journey.